

Press Release

Abliva AB (publ), 556595-6538
18 September 2023 09:00:00 CEST - Lund,
Sweden



Abliva to Participate in World Mitochondrial Disease Week 2023

Abliva AB (Nasdaq Stockholm: ABLI), a clinical-stage company developing drugs for the treatment of rare and severe primary mitochondrial disease, today announced that the company will participate in World Mitochondrial Disease Week 2023, which takes place on September 18 – 24, this year with the theme: fatigue. The week aims to increase global awareness and understanding of the disease. During the week, Abliva will release short videos each day with highlights of the ongoing activities at Abliva.

It is estimated that about 125 people per million are living with mitochondrial disease today. Many of them have several severe symptoms from parts of the body that require a great deal of energy. Some develop the disease as a child, while others are diagnosed well into adulthood. The two symptoms that are most frequently cited by patients as burdensome are chronic fatigue and progressive muscle weakness. For some, the disease brings a shortened lifespan. Several measures have been taken to facilitate drug development in rare disease (e.g. the Orphan Drug Act), but for systemic mitochondrial disease there are no approved medicines available.

World Mitochondrial Disease Week 2023 takes place on September 18 – 24, this year with the theme: fatigue. During the week, Abliva will publish videos focused on the disease, the important role that patients play in drug development, and the company's own drug development programs, including the ongoing FALCON study. Starting September 18, Abliva's videos will be posted daily on the company's website, <https://abliva.com/posts/events-and-presentations/world-mitochondrial-disease-week-2023/>, [YouTube channel](#), and [LinkedIn page](#).

World Mitochondrial Disease Week is an annual event that takes place during the third week of September. It is an initiative of the patient organization International mito patients (IMP), and individuals and local patient advocacy groups all over the world are engaged in spreading knowledge about the disease as well as advocacy and fundraising activities. Go to <https://mitochondrialdiseaseweek.org> for more information.

Press Release

Abliva AB (publ), 556595-6538
18 September 2023 09:00:00 CEST - Lund,
Sweden



For more information, please contact:

Catharina Johansson, Deputy CEO, CFO & VP Investor Relations
+46 (0)46-275 62 21, ir@abliva.com

Abliva AB (publ)

Medicon Village, SE-223 81 Lund, Sweden
Tel: +46 (0)46 275 62 20 (switchboard)
info@abliva.com, www.abliva.com

Subscribe to our news: <https://abliva.com/posts/news-subscription/>
Follow us on LinkedIn: <https://www.linkedin.com/company/abliva>
Subscribe to our YouTube channel: <https://www.youtube.com/channel/UChqP7Ky5caXtp72CELhD6Mg>

Abliva – Delivering mitochondrial health

Abliva discovers and develops medicines for the treatment of mitochondrial disease. This rare and often very severe disease occurs when the cell's energy provider, the mitochondria, do not function properly. The company has prioritized two projects. KL1333, a powerful regulator of the essential co-enzymes NAD⁺ and NADH, has entered late-stage development. NV354, an energy replacement therapy, has completed preclinical development. Abliva, based in Lund, Sweden, is listed on Nasdaq Stockholm, Sweden (ticker: ABLI).

Attachments

[Abliva to Participate in World Mitochondrial Disease Week 2023](#)